Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Orally active iron chelators in development at Novartis

Feb. 16, 1998

TheraTech and SmithKline Beecham join forces on nicotine product

Feb. 3, 1998

Dual 5-HT reuptake inhibitors/5-HT1A antagonists developed at Lilly

Jan. 26, 1998

New chelating agent developed by Israeli researchers

Jan. 21, 1998

U.K. launch for inhaled nicotine replacement therapy

Dec. 23, 1997

Antizol cleared by FDA as first antidote for ethylene glycol poisoning

Dec. 19, 1997

U. of Florida prepares new metal chelators

Dec. 18, 1997

AMPA antagonist investigated for treatment of drug withdrawal

Dec. 9, 1997

FDA clears IND for ImmuLogic's cocaine vaccine

Dec. 5, 1997

Alza and SmithKline Beecham expand Nicoderm marketing agreement

Nov. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...